8 recruiting, 3 completed, 3 withdrawn, 2 active not recruiting. 13 Phase 2, 10 Phase 1, 3 Phase 3.
Follow Immunocore Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp Dexamethasone - Uveal Melanoma, Metastatic | Phase 2 | Not yet recruiting | University of California, San Diego | 34 | 2026-11-01 | 2026-09-03 |
| Study of IMC-S118AI in Type 1 Diabetes IMC-S118AI - Type 1 Diabetes, Type 1 Diabetes (T1D) | Phase 1 | Not yet recruiting | Immunocore Ltd | 154 | 2026-04-01 | 2026-03-25 |
| Neoadjuvant Tebentafusp for Uveal Melanoma Tebentafusp-Tebn - Locally Advanced Unresectable Uveal Melanoma | Phase 2 | Recruiting | Thomas Jefferson University | 19 | 2025-09-05 | 2026-06-12 |
| Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma Tebentafusp - Uveal Melanoma | Phase 2 | Recruiting | Diwakar Davar | 44 | 2025-08-18 | 2026-09-09 |
| Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization - Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver | Phase 2 | Recruiting | University of Miami | 30 | 2025-02-14 | 2026-02-23 |
| Adjuvant Tebentafusp in High Risk Ocular Melanoma Tebentafusp - Uveal Melanoma | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 290 | 2024-11-11 | 2026-06-30 |
| Study of IMC-P115C in Advanced PRAME-Positive Cancers IMC-P115C - PRAME Positive, Cancer | Phase 1 | Recruiting | Immunocore Ltd | 140 | 2024-11-07 | 2026-02-25 |
| IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) Brenetafusp, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Immunocore Ltd | 680 | 2024-06-05 | 2026-02-25 |
| Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers IMC-R117C, Chemotherapy drug, Kinase inhibitor - Cancer, HLA-A*02:01-positive | Phase 1 / Phase 2 | Recruiting | Immunocore Ltd | 600 | 2024-01-10 | 2026-01-28 |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice - Advanced Melanoma | Phase 3 | Recruiting | Immunocore Ltd | 540 | 2022-12-19 | 2026-02-25 |
| Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma Tebentafusp - Melanoma (Skin), Melanoma, Uveal | Phase 2 | Active not recruiting | University of Oxford | 850 | 2022-07-25 | 2025-07-17 |
| Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD - Hepatitis B, Chronic | Phase 1 | Withdrawn | Immunocore Ltd | 2020-08-12 | 2024-10-15 | |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy - Select Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Immunocore Ltd | 410 | 2020-02-25 | 2026-03-06 |
| Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab IMC-C103C, Atezolizumab - Select Advanced Solid Tumors | Phase 1 / Phase 2 | Withdrawn | Immunocore Ltd | 2019-05-17 | 2024-10-18 | |
| Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers IMCnyeso - Select Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Immunocore Ltd | 29 | 2018-06-15 | 2022-03-11 |
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma IMCgp100, Dacarbazine, Ipilimumab - Uveal Melanoma | Phase 2 | Completed | Immunocore Ltd | 378 | 2017-10-16 | 2026-10-29 |
| IMCgp100-401 Rollover Study IMCgp100 - Malignant Melanoma | Phase 2 | Terminated | Immunocore Ltd | 3 | 2017-01-11 | 2020-07-27 |
| A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma IMCgp100 - Uveal Melanoma | Phase 1 / Phase 2 | Completed | Immunocore Ltd | 146 | 2016-02-29 | 2023-03-21 |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma Tebentafusp (IMCgp100) - Malignant Melanoma | Phase 1 / Phase 2 | Withdrawn | Immunocore Ltd | 2015-11-01 | 2024-07-24 | |
| Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma IMCgp100 - Malignant Melanoma | Phase 1 | Completed | Immunocore Ltd | 84 | 2010-09-28 | 2020-07-08 |
Showing 20 of 21. Sign in to see all of them.
Uveal Melanoma (10) · Melanoma (8) · Neoplasms (2) · Cytokine Release Syndrome (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Diabetes Mellitus, Type 1 (1) · Hepatitis B, Chronic (1) · Neoplasm Metastasis (1) · Nevus, Blue (1)
tebentafusp (9) · pembrolizumab (3) · Antibodies, Monoclonal (2) · Angiogenesis Inhibitors (1) · Bevacizumab (1) · Calcium Dobesilate (1) · Dacarbazine (1) · Dexamethasone (1) · Drug Therapy (1) · Ipilimumab (1) · Nivolumab (1) · Opdualag (1) · atezolizumab (1) · mycophenolic adenine dinucleotide (1) · relatlimab (1)
United States (16) · United Kingdom (12) · Spain (10) · Australia (7) · Germany (7) · Belgium (6) · Canada (6) · France (6) · Italy (6) · Poland (5) · Netherlands (4) · Switzerland (4) · Austria (3) · Brazil (2) · Denmark (2)
Diwakar Davar, MD, PhD (1) · Lynn Feun, MD (1) · Mark Middleton (1) · Namir Hassan, PhD (1) · Paul Nathan (1) · Richard D. Carvajal (1) · Rino Seedor, MD (1) · Serge Leyvraz (1) · Soo Park, MD (1)
PMID 34551229, PMID 36229663, PMID 37286303, PMID 37870955, PMID 40054461, PMID 42162665, PMID 42476725, PMID 42935816
2023 (3), 2019 (2)